CLL Tools and Downloads
Click on the following thumbnails for Adobe downloads of patient treatment aids:
Understanding CLL: A Guide for Patients Who Want to Take Charge of Chronic
Lymphocytic Leukemia
Here's a comprehensive brochure that summarizes key information about CLL and provides tools for managing treatment.
Download a PDF of Understanding CLL: A Guide for Patients Who Want to Take Charge of Chronic Lymphocytic Leukemia
A Patient-Friendly List of Terms
This tool is a glossary of terms associated with CLL that will help patients to better understand their reading about the illness and available treatments.
Download a PDF of A Patient-Friendly List of Terms
Sample Treatment Schedule
Campath patients and their doctors will develop a personalized Campath treatment schedule that works best for them. Here's what a treatment schedule looks like.
View a Sample Treatment Schedule
CamCare™ Brochure
The CamCare Brochure is a summary of the benefits of the CamCare program. It tells patients how to take advantage of a 24-hour support system with expert nurses.
Download a PDF of the CamCare Brochure
Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).
WARNING: CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS
Cytopenias: Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia [see WARNINGS AND PRECAUTIONS (5.1)].
Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days [see DOSAGE AND ADMINISTRATION (2) and WARNINGS AND PRECAUTIONS (5.2)].
Infections: Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.3)].
The most commonly reported adverse reactions are infusion reactions fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings and Precautions," and "Adverse Reactions" sections of full Prescribing Information.
Please see Full Prescribing Information (PDF).
